Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies.
| Autor: | Reed DR; Department of Medicine, Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, USA., Lum LG; Department of Medicine, Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert opinion on biological therapy [Expert Opin Biol Ther] 2024 Aug; Vol. 24 (8), pp. 761-772. Date of Electronic Publication: 2024 Jul 29. |
| DOI: | 10.1080/14712598.2024.2384086 |
| Abstrakt: | Introduction: Since the approval of the bispecific antibody blinatumomab in 2017 for the treatment of acute lymphoblastic leukemia in relapse, the development of numerous bispecific antibody constructs has dramatically expanded in hematologic malignancies. Many have recently received Food Drug Administration and European Medicines Agency approvals in various stages of treatment for lymphomas, leukemias, and multiple myeloma. Areas Covered: The purpose of this review is to provide an overview of bispecific antibody treatment including the mechanisms leading to effector T cells targeting tumor-associated antigens, the treatment indications, efficacies, toxicities, and challenges of the different constructs. A literature search was performed through access to PubMed and clinicaltrials.gov. Expert Opinion: While there has been substantial success in the treatment of NHL, MM, and ALL, there are still hematologic malignancies such as AML where there has been limited progress. It is important to continue to investigate new designs, tumor antigen targets, and further refine where current approved bispecific antibodies fit in terms of sequencing of therapy. Hopefully, with the knowledge gained in recent years and the explosion of these therapies, patients with blood cancers will continue to benefit from these treatments for years to come. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|